Zacks Investment Research downgraded shares of PROSENA HLDG BV (RNA) from OUTPERFORM to NEUTRAL on November 18, 2014, with a target price of $13.50.
Prosensa Holding B.V. is a biotechnology company. It engaged in the discovery, development and commercialization of ribonucleic acid modulating therapeutics. The company is primarily focused on neuromuscular and neurodegenerative disorders, such as Duchenne Muscular Dystrophy, Myotonic Dystrophy and Huntington's disease. Prosensa Holding B.V. is based in Leiden, the Netherlands.
Get all Zacks Research Reports and be alerted to fast-breaking buy and sell opportunities every trading day.
To get a free copy of the research report on PROSENA HLDG BV (RNA),
click here.
For more information about research offerings from Zacks Investment Research, visit
Zacks.com .
Be the first to comment